Abstract |
Infant botulism is a paralytic syndrome which manifests as a result of ingesting spores of the toxin secreting bacterium Clostridium botulinum by infants. As opposed to botulism in adults, treating infant botulism with horse antiserum was not approved due to several safety issues. This restriction has led to the development of Human Botulism Immune Globulin Intravenous (BIG-IV; sells under BabyBIG). In this article we review infant botulism and the advantages of treating it with BIG-IV.
|
Authors | Absalom Falk, Amichay Afriat, Yechiel Hubary, Lior Herzog, Arik Eisenkraft |
Journal | Harefuah
(Harefuah)
Vol. 153
Issue 3-4
Pg. 180-3, 238
( 2014)
ISSN: 0017-7768 [Print] Israel |
PMID | 24791561
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Immunoglobulins
- Immunologic Factors
- botulism immune globulin
|
Topics |
- Age Factors
- Botulism
(drug therapy, microbiology, physiopathology)
- Clostridium botulinum
(isolation & purification)
- Humans
- Immunoglobulins
(therapeutic use)
- Immunologic Factors
(therapeutic use)
- Infant
|